WS
GLMD icon

Wedbush Securities’s Galmed Pharmaceuticals GLMD Stock Holding History

Wedbush Securities’s Portfolio GLMD Stock Details GLMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-72
Closed -$46K – 919
2020
Q3 		$46K Buy
+72
New +$58.8K ﹤0.01% 890

Other funds holding GLMD

NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
II
Ibex Investors Denver, Colorado $152M AUM 19.17% 1-Year Est. Return
PAWC
P.A.W. Capital Greenwich, Connecticut $88.2M AUM 25.13% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
RJA
Raymond James & Associates St Petersburg, Florida $164B AUM 33.91% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Rockefeller Capital Management
Rockefeller Capital Management New York $56.4B AUM 24.96% 1-Year Est. Return

Wedbush Securities's GLMD Position: Q4 2020 in Review

Wedbush Securities sold out of Galmed Pharmaceuticals (GLMD) in Q4 2020, closing a stake of 72 shares — an estimated $46K sold.

Wedbush Securities first reported a position in GLMD in Q3 2020 and held it in 1 quarter. The position peaked at $46K in Q3 2020. 21 funds tracked by Wall St. Rank hold GLMD as of Q4 2020.

  • Wedbush Securities reported no remaining Galmed Pharmaceuticals position as of Q4 2020 after selling out during the quarter.
  • Wedbush Securities sold 72 Galmed Pharmaceuticals shares in Q4 2020, an estimated $46K.
  • Wedbush Securities first reported a position in Galmed Pharmaceuticals in Q3 2020 and held it in 1 quarter.
  • Wedbush Securities's Galmed Pharmaceuticals position peaked at $46K in Q3 2020.
  • 21 funds tracked by Wall St. Rank held Galmed Pharmaceuticals as of Q4 2020.

Based on Wedbush Securities's 13F filing for Q4 2020, filed 16 Feb 2021.